aVaxziPen develops thermally stable, needle-free solid dose vaccines that deliver precise doses with minimal waste, significantly reducing the risk of needle stick injuries and sharps waste. Their technology enhances immunogenicity, achieving up to 200 times greater antibody responses while using up to nine times less antigen, addressing the challenges of vaccine stability and distribution efficiency.
Funding
$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional liquid vaccines often require refrigeration, making them difficult to distribute and administer in resource-limited settings. Needle-based delivery poses risks of needle-stick injuries, sharps waste, and needle phobia, further complicating vaccination efforts.
Solution
aVaxziPen develops thermally stable, needle-free solid dose vaccines that enhance vaccine delivery and efficacy. The solid dose formulation eliminates the need for refrigeration, simplifying storage and distribution, especially in remote areas. The needle-free delivery system uses a device smaller than a grain of rice to administer an accurate dose, dissolving quickly and painlessly. Preclinical studies have demonstrated significantly higher antibody responses with aVaxziPen's solid dose vaccines, even with reduced antigen doses.
Target Audience
The primary target audience includes global health organizations, government agencies, and pharmaceutical companies seeking to improve vaccine distribution, reduce healthcare waste, and enhance vaccine efficacy, particularly in developing countries.
Features
- Thermally stable solid dose formulation maintains vaccine integrity at temperatures up to 50°C for extended periods.
- Needle-free delivery system eliminates the risk of needle-stick injuries and sharps waste.
- Precise dosing ensures accurate vaccine administration with minimal waste.
- Demonstrated up to 200 times greater antibody responses in preclinical studies compared to liquid vaccines.
- Achieved equivalent immune response using up to nine times less antigen.
- Reduced carbon footprint compared to traditional needle and syringe delivery.